



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/525,266
				Filing Date	August 21, 2003
				First Named Inventor	Ong et al.
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	7	Attorney Docket Number	20747/240 (ARDCK/P32478US)

U.S. PATENT DOCUMENTS					
Examiner Initials [*]	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
/S.M./ ↓	1	US-4,411,890	10-25-1983	Momany	
	2	US-6,025,471	02-15-2000	Deghenghi	

FOREIGN PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
/S.M./ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓	3	WO 89/07110	08-10-1989	Bowers et al.		
	4	WO 89/07111	08-10-1989	Bowers et al.		
	5	WO 93/04081	03-04-1993	Bowers et al.		
	6	WO 96/15148	05-23-1996	Somers et al.		
	7	WO 98/22124	05-28-1998	Berti et al.		
	8	WO 00/09537	02-24-2000	Bowers et al.		
	9	WO 00/23097	04-27-2000	Rudling		
	10	WO 00/67770	11-16-2000	Isgaard et al.		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
/S.M./	11	AVALLONE et al., "Growth Hormone-Releasing Peptides as Novel Regulators of the PPAR-LXR-ABC Cascade," Poster Presentation at ENDO 2003, Philadelphia, PA, Abstract #P3-275 (June 19-22, 2003)		
↓	12	BODART et al., "CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart," <i>Cir. Res.</i> 90:844-849 (2002)		
	13	BODART et al., "Identification and Characterization of a New Growth Hormone-Releasing Peptide Receptor in the Heart," <i>Circ. Res.</i> 85:796-802 (1999)		
	14	BOWERS et al., "On the <i>in Vitro</i> and <i>in Vivo</i> Activity of a New Synthetic Hexapeptide that Acts on the Pituitary to Specifically Release Growth Hormone," <i>Endocrinology</i> 114(5):1537-1545 (1984)		

Examiner Signature	/Stacey Macfarlane/	Date Considered	11/27/2007
-----------------------	---------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		10/525,266	
				Filing Date		August 21, 2003	
				First Named Inventor		Ong et al.	
				Group Art Unit		To Be Assigned	
				Examiner Name		To Be Assigned	
Sheet	2	of	7	Attorney Docket Number		20747/240 (ARDCK/P32478US)	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/S.M./	15	BOWERS et al., "Structure-Activity Relationships of a Synthetic Pentapeptide that Specifically Releases Growth Hormone <i>in Vitro</i> ," <i>Endocrinology</i> 106(3):663-667 (1980)	
	16	BOWERS, "GH Releasing Peptides - Structure and Kinetics," <i>J. Pediatr. Endocrinol.</i> 6:21-31 (1993)	
	17	BOWERS, "Growth Hormone-Releasing Peptide (GHRP)," <i>Cell. Mol. Life Sci.</i> 54:1316-1329 (1998)	
	18	BOWERS, "Xenobiotic Growth Hormone Secretagogues: Growth Hormone Releasing Peptides," <i>Xenobiotic Growth Hormone Secretagogues</i> , Springer-Verlag, New York; Eds. Bereu, B. & Walker, R.F., Chapter 2, pp.9-28 (1996)	
	19	BROGLIO et al., "Effects of Acute Hexarelin Administration on Cardiac Performance in Patients with Coronary Artery Disease During By-Pass Surgery," <i>Eur. J. Pharmacology</i> 448:193-200 (2002)	
	20	BUJOLD et al., "Growth Hormone-Releasing Peptides (GHRPs) Treatment Modulated Plasma Lipid Profile and the Scavenger Receptor Expression Within Macrophages," Presented at AFPC Conference 2003, Montreal, Canada, Abstract #A30 (May 29-June 1, 2003)	
	21	CAMANNI et al., "Growth Hormone-Releasing Peptides and Their Analogs," <i>Front. Neuroendocrinol.</i> 19:47-72 (1998)	
	22	CHAWLA et al., "A PPAR γ -LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis," <i>Molecular Cell</i> 7:161-171 (2001)	
	23	CHAWLA et al., "PPAR- γ Dependent and Independent Effects on Macrophage-Gene Expression in Lipid Metabolism and Inflammation," <i>Nature Med.</i> 7(1):48-52 (2001)	
	24	CHINETTI et al., "PPAR- α and PPAR- γ Activators Induce Cholesterol Removal from Human Macrophage Foam Cells Through Stimulation of the ABCA1 Pathway," <i>Nature Med.</i> 7(1):53-58 (2001)	
↓	25	CHISOLM III et al., "The Oxidation of Lipoproteins by Monocytes-Macrophages," <i>J. Biol. Chem.</i> 274(37):25959-25962 (1999)	

Examiner Signature	/Stacey Macfarlane/	Date Considered	11/27/2007
--------------------	---------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/525,266
				Filing Date	August 21, 2003
				First Named Inventor	Ong et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	3	of	7	Attorney Docket Number	20747/240 (ARDCK/P32478US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/S.M./	26	COLONNA et al., "Cardiac Ischemia and Impairment of Vascular Endothelium Function in Hearts from Growth Hormone-Deficient Rats: Protection by Hexarelin," <i>Eur. J. Pharmacol.</i> 334:201-207 (1997)	
	27	DE WINTHER & HOFKER, "Scavenging New Insights Into Atherogenesis," <i>J. Clin. Invest.</i> 105(8):1039-1041 (2000)	
	28	DEGHENGHI et al., "Small Peptides as Potent Releasers of Growth Hormone," <i>J. Ped. End. Metab.</i> 8:311-313 (1995)	
	29	DEGHENGHI, "Growth Hormone Releasing Peptides," <i>Xenobiotic Growth Hormone Secretagogues</i> , Springer-Verlag, New York; Eds. Bereu, B. & Walker, R.F., Chapter 6, pp.85-102 (1996)	
	30	DEGHENGHI, "The Development of 'Impervious Peptides' as Growth Hormone Secretagogues," <i>Acta Paediatr. Suppl.</i> 423:85-87 (1997)	
	31	DEMERS et al., "Détermination du Site de Liaison de L'Hexaréline sure le Récepteur Scavenger CD36," Presented at AFPC Conference 2003, Montreal, Canada, Abstract #A26 (May 19-23, 2003)	
	32	DEMERS et al., "Determination of Hexarelin Binding Domain on the Scavenger Receptor CD36," Poster Presentation at ENDO 2003, Philadelphia, PA, Abstract #P2-225 (June 19-22, 2003)	
	33	DICKSON et al., "Systemic Administration of Growth Hormone-Releasing Peptide Activates Hypothalamic Arcuate Neurons," <i>Neuroscience</i> 53(2):303-306 (1993)	
	34	FEBBRAIO et al., "CD36: A Class B Scavenger Receptor Involved in Angiogenesis, Atherosclerosis, Inflammation, and Lipid Metabolism," <i>J. Clin. Invest.</i> 108(6):785-791 (2001)	
	35	FEBBRAIO et al., "Targeted Disruption of the Class B Scavenger Receptor CD36 Protects Against Atherosclerotic Lesion Development in Mice," <i>J. Clin. Invest.</i> 105(8):1049-1056 (2000)	
↓	36	FENG et al., "Induction of CD36 Expression by Oxidized LDL and IL-4 by a Common Signaling Pathway Dependent on Protein Kinase C and PPAR-γ," <i>J. Lipid Res.</i> 41:688-696 (2000)	

Examiner Signature	/Stacey Macfarlane/	Date Considered	11/27/2007
--------------------	---------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known			
				Application Number		10/525,266	
				Filing Date		August 21, 2003	
				First Named Inventor		Ong et al.	
				Group Art Unit		To Be Assigned	
				Examiner Name		To Be Assigned	
Sheet	4	of	7	Attorney Docket Number		20747/240 (ARDCK/P32478US)	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/S.M./	37	GAYET, "L'essentiel de 1999 dans la maladie coronaire," <i>Arch. Des Maladies Du Coeur et des Vaisseaux</i> 93(1 Spec No):51-59 (2000)	X
	38	GHIGO et al., "Endocrine and Non-Endocrine Activities of Growth Hormone Secretagogues in Humans," <i>Horm. Res.</i> 51(Suppl. 3):9-15 (1999)	
	39	GHIGO et al., "Growth Hormone-Releasing Peptides," <i>Eur. J. Endocrinol.</i> 136:445-460 (1997)	
	40	GLASS & WITZTUM, "Atherosclerosis: The Road Ahead," <i>Cell</i> 104:503-516 (2001)	
	41	HEGYI et al., "Macrophage Death and the Role of Apoptosis in Human Atherosclerosis," <i>J. Hematotherapy & Stem Cell Res.</i> 10:27-42 (2001)	
	42	HODEL, "Myopathy and Rhabdomyolysis with Lipid-Lowering Drugs," <i>Toxicol. Lett.</i> 128:159-168 (2002)	
	43	HUBER et al., "Interleukin-6 Exacerbates Early Atherosclerosis in Mice," <i>Arterioscler. Thromb. Vasc. Biol.</i> 19:2364-2367 (1999)	
	44	JANABI et al., "Oxidized LDL-Induced NF- κ B Activation and Subsequent Expression of Proinflammatory Genes Are Defective in Monocyte-Derived Macrophages From CD36-Deficient Patients," <i>Arterioscler. Thromb. Vasc. Biol.</i> 20:1953-1960 (2000)	
	45	KIECHL et al., "The Natural Course of Atherosclerosis. Part I: Incidence and Progression," <i>Arterioscler. Thromb. Vasc. Biol.</i> 19:1484-1490 (1999)	
	46	KOJIMA et al., "Purification and Distribution of Ghrelin: The Natural Endogenous Ligand for the Growth Hormone Secretagogue Receptor," <i>Horm. Res.</i> 56(Suppl. 1):93-97 (2001)	
	47	LAU et al., "Severe Rhabdomyolysis Associated with the Cerivastatin-Gemfibrozil Combination Therapy," <i>Texas Heart Institute J.</i> 28(2):142-145 (2001)	
	48	MAOR et al., "Oxidized Monocyte-Derived Macrophages in Aortic Atherosclerotic Lesion from Apolipoprotein E-Deficient Mice and from Human Carotid Artery Contain Lipid Peroxides and Oxysterols," <i>Biochem. Biophys. Res. Commun.</i> 269:775-780 (2000)	

Examiner Signature	/Stacey Macfarlane/	Date Considered	11/27/2007
--------------------	---------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/525,266
				Filing Date	August 21, 2003
				First Named Inventor	Ong et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	5	of	7	Attorney Docket Number	20747/240 (ARDCK/P32478US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/S.M./	49	MARLEAU et al., "Effect of Growth Hormone Releasing Peptides (GHRPs) on Monocyte/Macrophage Scavenger Receptors (SR) B (CD36) Expression and Monocyte Trafficking," <i>Inflammation Research</i> 50(Supplement 3):S154 (2001), Presented at Fifth World Congress of Inflammation, Edinburgh, Scotland, Abstract #06/02 (September 22-26, 2001)	
	50	MARLEAU et al., "Growth Hormone Releasing Peptides as a New Therapy for Atherosclerosis," Sixth International Inflammation Conference, Vancouver, Canada, Abstract (August 2003)	
	51	MOMANY et al., "Conformational Energy Studies and <i>in Vitro</i> and <i>in Vivo</i> Activity Data on Growth Hormone-Releasing Peptides," <i>Endocrinology</i> 114(5):1531-1536 (1984)	
	52	MOMANY et al., "Design, Synthesis, and Biological Activity of Peptides which Release Growth Hormone <i>in Vitro</i> ," <i>Endocrinology</i> 108(1):31-39 (1981)	
	53	MOORE et al., "The Role of PPAR- γ in Macrophage Differentiation and Cholesterol Uptake," <i>Nature Med.</i> 7(1):41-47 (2001)	
	54	NAGY et al., "Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPAR γ ," <i>Cell</i> 93:229-240 (1998)	
	55	NAKATA et al., "CD36, a Novel Receptor for Oxidized Low-Density Lipoproteins, Is Highly Expressed on Lipid-Laden Macrophages in Human Atherosclerotic Aorta," <i>Arterioscler. Thromb. Vasc. Biol.</i> 19:1333-1339 (1999)	
	56	NICHOLSON et al., "CD36 in Atherosclerosis. The Role of a Class B Macrophage Scavenger Receptor," <i>Ann. New York Acad. Sci.</i> pp.128-133 (2000)	
	57	NICHOLSON et al., "Oxidized LDL Binds to CD36 on Human Monocyte-Derived Macrophages and Transfected Cell Lines," <i>Arterioscler. Thromb. Vasc. Biol.</i> 15:269-275 (1995)	
	58	NOZAKI et al., "Reduced Uptake of Oxidized Low Density Lipoproteins in Monocyte-Derived Macrophages from CD36-Deficient Subjects," <i>J. Clin. Invest.</i> 96:1859-1865 (1995)	
↓	59	ONG et al., "Growth Hormone-Releasing Peptides as Inhibitors of Fatty Streaks Formation: A New Therapy for Atherosclerosis," Poster Presentation at ENDO 2003, Philadelphia, PA, Abstract #P2-223 (June 19-22, 2003)	

Examiner Signature	/Stacey Macfarlane/	Date Considered	11/27/2007
--------------------	---------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/525,266
				Filing Date	August 21, 2003
				First Named Inventor	Ong et al.
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	6	of	7	Attorney Docket Number	20747/240 (ARDCK/P32478US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/S.M./	60	ONG et al., "Growth Hormone-Releasing Peptides as Negative Modulators of Atherosclerosis and Hypercholesterolemia," Presented at Fourth Symposium on Growth Hormone Secretagogues, Tampa, FL (November 7-10, 2002)	
	61	ONG et al., "Physiological Function of Growth Hormone Secretagogue Receptors in the Cardiovascular System," <i>Peptides and Non-Peptides of Oncologic and Neuroendocrine Relevance: From Basic to Clinical Research</i> , Springer-Verlag, Ed.: Müller, E.E., Chapter 12, pp.117-127 (2003)	
	62	PODREZ et al., "Macrophage Scavenger Receptor CD36 is the Major Receptor for LDL Modified by Monocyte-Generated Reactive Nitrogen Species," <i>J. Clin. Invest.</i> 105(8):1095-1108 (2000)	
	63	ROSENFELD et al., "Advanced Atherosclerotic Lesions in the Innominate Artery of the ApoE Knockout Mouse," <i>Arterioscler. Thromb. Vasc. Biol.</i> 20:2587-2592 (2000)	
	64	ROSSONI et al., "Protectant Activity of Hexarelin of Growth Hormone Against Postischemic Ventricular Dysfunction in Hearts from Aged Rats," <i>J. Cardiovasc. Pharmacol.</i> 32:260-265 (1998)	
	65	SCHOEN et al., "Section IV. Immunology, Endocrinology and Metabolic Diseases," <i>Ann. Rep. Med. Chem.</i> 28:177-186 (1993)	
	66	SILVERSTEIN & FEBBRAIO, "CD36 and Atherosclerosis," <i>Curr. Opin. Lipidol.</i> 11:483-491 (2000)	
	67	TREMBLAY et al., "Growth Hormone-Releasing Peptides as Novel Regulators of the Nuclear Receptor PPARgamma in Macrophage," Presented at FEBS 2003, Brussels, Belgium, Abstract #537 (July 3-8, 2003)	
	68	VEERARAGAVAN et al., "Growth Hormone-Releasing Peptide (GHRP) Binding to Porcine Anterior Pituitary and Hypothalamic Membranes," <i>Life Sci.</i> 50:1149-1155 (1992)	
	69	WALKER et al., "Effects of Stimulated Growth Hormone Secretion on Age-Related Changes in Plasma Cholesterol and Hepatic Low Density Lipoprotein Messenger RNA Concentrations," <i>Mechanisms of Ageing and Development</i> 75:215-226 (1994)	
	70	WANG et al., "Effect of Growth Hormone Releasing Peptides on Fatty Streak Formation and Lipid Uptake by Macrophages in Apolipoprotein E Deficient (APOE -/-) Atherosclerotic Mice," Presented at AFPC Conference 2003, Montreal, Canada, Abstract #A26 (May 29-June 1, 2003)	

Examiner Signature	/Stacey Macfarlane/	Date Considered	11/27/2007
--------------------	---------------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

Examiner Signature	/Stacey Macfarlane/	Date Considered	11/27/2007
-----------------------	---------------------	--------------------	------------

* **EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.